45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
130 citations
,
September 1990 in “Journal of the American Academy of Dermatology” Flutamide effectively reduced excessive hair growth and improved related symptoms in hirsutism patients without significant side effects.
15 citations
,
January 2018 in “Acta dermato-venereologica” Finasteride and dutasteride increase sexual dysfunction risk by 1.57 times in male hair loss treatment.
29 citations
,
July 2012 in “The Journal of Sexual Medicine” Rats had lasting erectile problems after stopping a certain medication.
September 2025 in “Reactions Weekly”
9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
January 1999 in “Salina: revista de lletres” Ashwagandha may help reduce symptoms of adrenal hyperplasia.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
March 2023 in “Oxford University Press eBooks”
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
November 2023 in “Bioorganic Chemistry” Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
July 2026 in “Journal of the American Academy of Dermatology”
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Dutasteride more effective than finasteride for hair growth; SM04554 safe and potentially effective for hair loss.
May 2023 in “Journal of Drugs in Dermatology” REVIVV® serum improves hair growth and reduces shedding in androgenetic alopecia.
February 1999 in “Strength and Conditioning Journal” Androstenedione, a hormone supplement, doesn't improve muscle or performance and can cause harmful side effects.
March 2013 in “The Journal of Urology” Non-daily Dutasteride is more cost-effective and has lower cancer incidence than daily treatment.
2 citations
,
February 2007 in “PubMed” Dutasteride is cheaper than finasteride for treating benign prostatic hyperplasia.
10 citations
,
December 2005 in “Aktuelle Dermatologie” Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
September 2023 in “Journal of the American Academy of Dermatology” 164 citations
,
January 2003 in “Drugs”
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
September 2024 in “Chemico-Biological Interactions” Finasteride improves heart function in obese and aging male rats by reducing oxidative stress and p53 protein levels.
July 2025 in “International Journal of Dermatology” 58 citations
,
May 2004 in “British Journal of Dermatology” Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.
6 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
September 2025 in “JAAD International” Thrice-weekly dutasteride improved hair density and thickness more than twice-weekly, but not hair count compared to daily finasteride.